BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia

The management of chronic myeloid leukemia with BCR-ABL1 tyrosine kinase inhibitors has evolved chronic myeloid leukemia into a chronic, manageable disease. A patient-centered approach is important for the appropriate management of chronic myeloid leukemia and optimization of long-term treatment out...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuellar, Sandra, Vozniak, Michael, Rhodes, Jill, Forcello, Nicholas, Olszta, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094551/
https://www.ncbi.nlm.nih.gov/pubmed/28580869
http://dx.doi.org/10.1177/1078155217710553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094551/
https://www.ncbi.nlm.nih.gov/pubmed/28580869
http://dx.doi.org/10.1177/1078155217710553

Ejemplares similares